Vitamin B1 Analog Benfotiamine Prevents Diabetes-Induced Diastolic Dysfunction and Heart Failure Through Akt/Pim-1–Mediated Survival Pathway
- 1 March 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 3 (2) , 294-305
- https://doi.org/10.1161/circheartfailure.109.903450
Abstract
Background— The increasing incidence of diabetes mellitus will result in a new epidemic of heart failure unless novel treatments able to halt diabetic cardiomyopathy early in its course are introduced. This study aimed to determine whether the activity of the Akt/Pim-1 signaling pathway is altered at critical stages of diabetic cardiomyopathy and whether supplementation with vitamin B1 analog benfotiamine (BFT) helps to sustain the above prosurvival mechanism, thereby preserving cardiomyocyte viability and function. Methods and Results— Untreated streptozotocin-induced type 1 or leptin-receptor mutant type 2 diabetic mice showed diastolic dysfunction evolving to contractile impairment and cardiac dilatation and failure. BFT (70 mg/kg −1 /d −1 ) improved diastolic and systolic function and prevented left ventricular end-diastolic pressure increase and chamber dilatation in both diabetic models. Moreover, BFT improved cardiac perfusion and reduced cardiomyocyte apoptosis and interstitial fibrosis. In hearts of untreated diabetic mice, the expression and activity of Akt/Pim-1 signaling declined along with O- N -acetylglucosamine modification of Akt, inhibition of pentose phosphate pathway, activation of oxidative stress, and accumulation of glycation end products. Furthermore, diabetes reduced pSTAT3 independently of Akt. BFT inhibited these effects of diabetes mellitus, thereby conferring cardiomyocytes with improved resistance to high glucose-induced damage. The phosphoinositide-3-kinase inhibitor LY294002 and dominant-negative Akt inhibited antiapoptotic action of BFT-induced and Pim-1 upregulation in high glucose-challenged cardiomyocytes. Conclusions— These results show that BFT protects from diabetes mellitus-induced cardiac dysfunction through pleiotropic mechanisms, culminating in the activation of prosurvival signaling pathway. Thus, BFT merits attention for application in clinical practice.Keywords
This publication has 46 references indexed in Scilit:
- Nuclear and mitochondrial signalling Akts in cardiomyocytesCardiovascular Research, 2008
- Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemiaBiological Chemistry, 2008
- Protein Modification by O-Linked GlcNAc Reduces Angiogenesis by Inhibiting Akt Activity in Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Identification of the prosurvival activity of nerve growth factor on cardiac myocytesCell Death & Differentiation, 2007
- Akt Signaling and Growth of the HeartCirculation, 2006
- High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitusJournal of Applied Physiology, 2006
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failureJournal of Clinical Investigation, 2005
- Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper siteFEBS Letters, 2004
- Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitusThe American Journal of Cardiology, 2004
- Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene, 2000